Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VCYT 
Veracyte Inc (VCYT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VCYT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $41.22
1 Year Target Price $41.22
| 7 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.78% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.82B USD | Price to earnings Ratio 105.38 | 1Y Target Price 41.22 |
Price to earnings Ratio 105.38 | 1Y Target Price 41.22 | ||
Volume (30-day avg) 11 | Beta 2.12 | 52 Weeks Range 22.61 - 47.32 | Updated Date 10/17/2025 |
52 Weeks Range 22.61 - 47.32 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.5% | Operating Margin (TTM) 11% |
Management Effectiveness
Return on Assets (TTM) 1.98% | Return on Equity (TTM) 2.24% |
Valuation
Trailing PE 105.38 | Forward PE 28.01 | Enterprise Value 2532995680 | Price to Sales(TTM) 5.88 |
Enterprise Value 2532995680 | Price to Sales(TTM) 5.88 | ||
Enterprise Value to Revenue 5.29 | Enterprise Value to EBITDA 48.76 | Shares Outstanding 78671588 | Shares Floating 78235747 |
Shares Outstanding 78671588 | Shares Floating 78235747 | ||
Percent Insiders 0.48 | Percent Institutions 108.68 |
Upturn AI SWOT
Veracyte Inc
Company Overview
History and Background
Veracyte, Inc. was founded in 2008. It is a genomic diagnostics company that focuses on improving patient outcomes by resolving diagnostic uncertainty. It leverages machine learning and genomic technology to develop and commercialize diagnostic tests.
Core Business Areas
- Genomic Diagnostics: Develops and commercializes genomic tests for various diseases, including lung cancer, thyroid cancer, breast cancer and idiopathic pulmonary fibrosis.
Leadership and Structure
Marc Stapley is the current CEO. The company operates with a structure common to publicly traded biotech firms, with departments focused on R&D, commercial operations, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Afirma Genomic Sequencing Classifier (GSC): A genomic test used in thyroid cancer diagnosis to avoid unnecessary surgeries by refining the risk assessment of thyroid nodules. Market share data is difficult to obtain precisely, but Afirma GSC is a leading product in this space. Competitors include Interpace Biosciences, Exact Sciences, and various pathology labs offering molecular testing.
- Percepta Genomic Sequencing Classifier: A genomic test for lung cancer diagnosis, designed to improve diagnostic accuracy. Market share data is difficult to obtain precisely, but Percepta GSC is a prominent test used by pulmonologists. Competitors include Biodesix, Guardant Health, and Foundation Medicine (Roche).
- Envisia Genomic Classifier: A genomic test for idiopathic pulmonary fibrosis (IPF) diagnosis, aiming to improve the accuracy and speed of diagnosis. Market share data is difficult to obtain precisely. Competitors include other molecular diagnostic tests and traditional clinical assessment methods.
- Prosigna Breast Cancer Prognostic Gene Signature Assay: A test used in breast cancer prognosis to assess the risk of recurrence and guide treatment decisions. It is widely adopted. Competitors include Exact Sciences' Oncotype DX, Agendia's MammaPrint and NanoString's Prosigna.
Market Dynamics
Industry Overview
The genomic diagnostics industry is rapidly growing, driven by advances in sequencing technology and personalized medicine. Companies are focused on developing more accurate and less invasive diagnostic tests. Reimbursement and regulatory landscapes are continuously evolving.
Positioning
Veracyte is positioned as a leader in genomic diagnostics, particularly in areas of diagnostic uncertainty. Its competitive advantage lies in its proprietary genomic platforms and machine learning algorithms.
Total Addressable Market (TAM)
The global genomic testing market is expected to reach hundreds of billions of USD by 2030. Veracyte is positioning itself to capture a significant share of this market by focusing on specific disease areas where there is high unmet need.
Upturn SWOT Analysis
Strengths
- Proprietary genomic platforms
- Strong focus on diagnostic accuracy
- Established relationships with clinicians
- Use of machine learning
- FDA approved diagnostics
Weaknesses
- High research and development costs
- Dependence on reimbursement policies
- Competition from larger diagnostic companies
- Limited profitability
Opportunities
- Expanding into new disease areas
- Developing more personalized diagnostic tests
- Partnerships with pharmaceutical companies
- International expansion
- Increasing adoption of genomic testing
Threats
- Changes in reimbursement policies
- Increased competition
- Technological advancements that could render current tests obsolete
- Regulatory hurdles
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- EXAS
- PACB
- ILMN
- QDEL
Competitive Landscape
Veracyte faces strong competition from larger, more established diagnostic companies. Its competitive advantage lies in its specialized focus and proprietary genomic platforms. They are typically nimble in the space
Major Acquisitions
Decipher Biosciences
- Year: 2021
- Acquisition Price (USD millions): 600
- Strategic Rationale: Expanded Veracyte's genomic test offerings into urologic cancers.
Growth Trajectory and Initiatives
Historical Growth: Veracyte has exhibited revenue growth in recent years, driven by increased adoption of its genomic tests.
Future Projections: Analyst estimates vary, but generally project continued revenue growth for Veracyte, driven by new product launches and market expansion. These projections are dynamic and require continuous monitoring.
Recent Initiatives: Recent initiatives include expanding its genomic test portfolio and increasing its international presence.
Summary
Veracyte is a growing genomic diagnostics company with a strong focus on resolving diagnostic uncertainty. Its strengths lie in its proprietary technologies and targeted market areas, but faces challenges with competition and reimbursement. Recent acquisitions have broadened its product portfolio and growth potential, but careful cost management is critical. Overall, Veracyte has a favorable future in genomic diagnostics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Please do your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veracyte Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2013-10-30 | CEO & Director Mr. Marc A. Stapley | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 824 | Website https://www.veracyte.com |
Full time employees 824 | Website https://www.veracyte.com | ||
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.